- Previous close
2.8000 - Open
2.8200 - Bid 2.8000 x 372000
- Ask 2.8700 x 575400
- Day's range
2.8200 - 2.8200 - 52-week range
2.3700 - 3.8500 - Volume
1 - Avg. Volume
31,418 - Market cap (intra-day)
295.722M - Beta (5Y monthly) 0.37
- PE ratio (TTM)
25.64 - EPS (TTM)
0.1100 - Earnings date 21 Nov 2024
- Forward dividend & yield 0.02 (0.63%)
- Ex-dividend date 19 Jun 2024
- 1y target est
3.72
AFT Pharmaceuticals Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical products in New Zealand, Australia, Asia, and internationally. It offers products for use in the areas of allergy, gastrointestinal, cold and flu, digestive health, eye care, first aid, nail care, oral care, pain management, skin care, vitamins, and supplements, as well as other products. AFT Pharmaceuticals Limited was incorporated in 1997 and is headquartered in Auckland, New Zealand.
www.aftpharm.com110
Full-time employees
31 March
Fiscal year ends
Healthcare
Sector
Drug Manufacturers - Specialty & Generic
Industry
Recent news: AFT.NZ
View more
Performance overview: AFT.NZ
Trailing total returns as of 27/11/2024, which may include dividends or other distributions. Benchmark is
.YTD return
1-year return
3-year return
5-year return
Compare to: AFT.NZ
Select to analyse similar companies using key performance metrics; select up to four stocks.
Statistics: AFT.NZ
View moreValuation measures
Market cap
293.63M
Enterprise value
316.58M
Trailing P/E
25.02
Forward P/E
16.98
PEG ratio (5-yr expected)
--
Price/sales (ttm)
1.49
Price/book (mrq)
3.50
Enterprise value/revenue
1.61
Enterprise value/EBITDA
13.92
Financial highlights
Profitability and income statement
Profit margin
7.99%
Return on assets (ttm)
9.67%
Return on equity (ttm)
19.38%
Revenue (ttm)
195.41M
Net income avi to common (ttm)
15.61M
Diluted EPS (ttm)
0.1100
Balance sheet and cash flow
Total cash (mrq)
12.04M
Total debt/equity (mrq)
36.67%
Levered free cash flow (ttm)
10.16M